Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

FDA Issues Complete Response Letter for Lorcaserin New Drug Application

October 23, 2010 By Bio-Medicine.Org

SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 23, 2010
/PRNewswire-FirstCall/ — Arena Pharmaceuticals, Inc. (Nasdaq:
ARNA
) and Eisai Inc. announced that the US Food and Drug
Administration (FDA) issued a Complete Response Letter (CRL)
regarding Arena’s New Drug Application (NDA) for lorcaserin.
Lorcaserin is intended for weight management, including weight loss
and maintenance of weight loss, in patients who are obese (Body
Mass Index, or BMI, >/= 30) or patients who are overweight (BMI
>/= 27) and have at least one weight-related co-morbid
condition.

The FDA has completed its review of the NDA and determined that
it cannot approve the application in its present form. In the CRL,
the FDA outlined the non-clinical and clinical reasons for their
decision.

The non-clinical issues identified by the FDA included
diagnostic uncertainty in the classification of mammary masses in
female rats, unresolved exposure-response relationship for
lorcaserin-emergent mammary adenocarcinoma, and unidentified mode
of action and unclear safety margin for lorcaserin-emergent brain
astrocytoma.

The CRL included the following requests related to the
non-clinical issues: provide a detailed accounting of all slides
prepared from female rats that contributed to mammary tumor
incidence data in each update to the FDA and to the final study
report; in consultation with the FDA, identify an independent
pathologist or group of pathologists to re-adjudicate all mammary
and lung tissues (neoplastic and nonneoplastic lesions) from all
female rats; demonstrate that the apparent increase in
aggressiveness of adenocarcinoma in rats administered lorcaserin is
reasonably irrelevant to human risk assessment; and provide
additional data/information regarding the distribution of
lorcaserin to the CNS in animals and human subjects that would
clarify or provide a better estimate of astrocytoma exposure

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech